(IMCR) Immunocore Holdings plc Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(IMCR) Immunocore Holdings plc Complete Analysis Pack
Visual. Strategic. Downloadable.
This Immunocore Holdings plc 4P's Marketing Mix Analysis summarizes the company’s Product, Price, Place, and Promotion strategy and shows how these choices support positioning and sales; the page includes a real preview/sample of the report so you can review actual content and style before buying. Purchase the full version to get the complete ready-to-use analysis.
Product
1 marketed product: KIMMTRAK
KIMMTRAK is Immunocore Holdings plc’s only marketed product and lead revenue driver, turning the company into a commercial oncology business. In the latest reported full year, KIMMTRAK generated about $302.2 million in product revenue, up sharply year on year, showing strong uptake in metastatic uveal melanoma. It is a prescription immunotherapy, so the product sits at the center of Immunocore’s 4P mix and growth story.
Uveal melanoma indication
KIMMTRAK treats unresectable or metastatic uveal melanoma, a rare cancer with very few effective options, so Immunocore Holdings plc can focus on a tight specialty market. The U.S. sees about 2,000 to 3,000 new uveal melanoma cases each year, which keeps the indication small but high-value. That narrow label supports premium pricing and concentrated specialist sales.
TCR bispecific immunotherapy
KIMMTRAK is Immunocore Holdings plc’s TCR bispecific immunotherapy, built on its engineered T cell receptor platform and approved for unresectable or metastatic uveal melanoma in 2022. It redirects T cells to gp100 on cancer cells, so it attacks tumors in a way that differs from standard chemo or checkpoint drugs. That platform-led design is the product’s main edge in the market.
IMC-C103C Phase I/II
IMC-C103C is Immunocore Holdings plc’s Phase I/II dose-escalation oncology asset, expanding the pipeline beyond the marketed product. It is being tested across multiple solid tumors, including NSCLC, gastric, head and neck, ovarian, and synovial sarcoma cancers.
The program matters because it broadens the addressable market from one approved drug to a multi-tumor development platform. Early-stage dose escalation is still about safety, tolerability, and early signal strength, so the key next data will be response depth and dose selection.
- Phase I/II dose escalation
- Multiple solid tumor focus
- NSCLC, gastric, head and neck
- Ovarian and synovial sarcoma
- Pipeline expansion beyond the marketed asset
IMC-I109V, IMC-M113V, autoimmune candidates
IMC-I109V is Immunocore Holdings plc’s Phase I/II candidate for chronic hepatitis B, while IMC-M113V is in preclinical work for HIV. The pipeline also includes targeted immunosuppression candidates for autoimmune disease, showing a broader move beyond oncology into viral and immune control. The mix spans early-stage assets, so value is tied to clinical readouts, not current product sales.
- IMC-I109V: Phase I/II, chronic hepatitis B
- IMC-M113V: preclinical, HIV
- Autoimmune: targeted immunosuppression pipeline
KIMMTRAK Drives Immunocore’s Revenue Growth
KIMMTRAK is Immunocore Holdings plc’s only marketed product and main revenue driver. In the latest reported full year, it generated about $302.2 million in product revenue, showing strong demand in metastatic uveal melanoma. Its TCR bispecific design is the core product edge.
| Metric | Data |
|---|---|
| Lead product | KIMMTRAK |
| FY product revenue | $302.2m |
| Target use | Uveal melanoma |
What is included in the product
Detailed Word Document
A concise, company-specific 4P analysis of Immunocore Holdings plc’s Product, Price, Place, and Promotion strategy, grounded in real-world biotech positioning.
Editable Excel File
Simplifies Immunocore’s 4Ps into a quick, clear snapshot that reduces research time and supports faster decision-making.
Reference Sources
Consolidates primary industry reports, clinical trial data, and regulatory filings to speed due diligence and validate key assumptions for Immunocore Holdings plc.
Place
Abingdon, United Kingdom HQ
Immunocore Holdings plc is based in Abingdon, Oxfordshire, United Kingdom, and its HQ anchors corporate, scientific, and commercial teams. In 2025, this site stayed central to global coordination as the business advanced KIMMTRAK, its approved T-cell receptor therapy. The Abingdon base supports decision-making across a 4P mix built around one flagship product and worldwide execution.
Specialty oncology centers
Specialty oncology centers are the right place for KIMMTRAK because it is a physician-led, HLA-A*02:01-specific treatment for unresectable or metastatic uveal melanoma, a rare cancer seen in only about 5 to 7 people per million each year. In the pivotal phase 3 trial, median overall survival was 21.7 months with KIMMTRAK versus 16.0 months with investigator’s choice, so expert centers matter for patient selection and monitoring. These centers also handle complex infusion and adverse-event management, which fits Immunocore Holdings plc’s high-acuity launch model.
Hospital infusion delivery
Immunocore Holdings plc’s KIMMTRAK is delivered through hospital and clinic infusion, not retail channels, so access is tied to oncology centers. This setup supports controlled dosing and close monitoring for infusion reactions and cytokine release syndrome, which is why the label requires supervised administration. In the phase 3 study, 378 patients with metastatic uveal melanoma were treated in this controlled setting.
Specialty distribution network
Immunocore Holdings plc uses specialty pharmacy and specialty distributor channels for KIMMTRAK, so access is tied to payer approval, limited-site stocking, and cold-chain handling. That fits a rare-disease model: the eligible patient pool is small, but each start is high value and tightly managed. The network also helps control inventory and dispense only after reimbursement checks.
- Specialty channel supports refrigerated delivery
- Payer checks reduce failed fills
- Managed inventory fits rare patient demand
Global clinical trial sites
Immunocore Holdings plc uses global, multi-site clinical trial sites to speed pipeline readouts across oncology, infectious disease, and autoimmune programs. This network widens patient access and helps the Company run studies across the U.S., Europe, and other key markets, so geographic reach is built into development, not added later.
- Multi-site trials support faster enrollment
- Expands access across three core disease areas
- Strengthens global geographic reach
Immunocore’s Rare-Cancer Reach Centers on Specialist Oncology Sites
Place for Immunocore Holdings plc is centered on specialist oncology hospitals and infusion centers, with KIMMTRAK limited to supervised administration for HLA-A*02:01-positive metastatic uveal melanoma. In 2025, the Company’s Abingdon HQ still anchored global control, while trial sites across the U.S. and Europe extended reach for a rare cancer affecting about 5 to 7 people per million a year.
| Place factor | Data point |
|---|---|
| HQ | Abingdon, UK |
| Use setting | Specialty oncology centers |
| Disease rarity | 5 to 7 per million yearly |
Preview Before You Purchase
Immunocore Holdings plc Reference Sources
The preview shown here is the actual Immunocore Holdings plc 4P's Marketing Mix analysis you’ll receive instantly after purchase—fully complete, editable, and ready to use with no surprises.
Promotion
Medical congress presentations
Immunocore uses oncology and immunology congresses to present trial data and pipeline updates to physicians, researchers, and payers. This matters because KIMMTRAK is already approved in 1 core oncology setting, so each data drop can shape adoption and trial interest. Congress talks also support future launches by keeping the science visible before and after the 2025 reporting cycle.
Peer-reviewed clinical data
Immunocore Holdings plc promotes KIMMTRAK with peer-reviewed data because rare-disease oncology buyers want proof, not claims. In the pivotal phase 3 trial, tebentafusp cut the risk of death by 49% and lifted median overall survival to 21.7 months versus 16.0 months with control. That kind of published evidence builds trust, supports adoption, and shows clear efficacy, safety, and differentiation.
Key opinion leader engagement
Immunocore Holdings plc leans on key opinion leaders because specialist physician advocacy is central in rare oncology launches, especially for uveal melanoma. KIMMTRAK was backed by phase 3 data showing a median overall survival of 21.7 months versus 16.0 months, giving KOLs a clear evidence base to explain value. That makes this a standard prescription-biologic promotion channel, with expert voices helping widen awareness across oncology.
Investor and regulatory updates
Immunocore Holdings plc uses earnings calls and regulatory releases to keep investors aligned on approvals and pipeline progress, with the stock story anchored by KIMMTRAK, its approved therapy for metastatic uveal melanoma. In 2025, this updates mix stayed critical because every new FDA, EMA, or MHRA filing can move confidence in the platform fast.
- Shares approval and trial milestones
- Supports trust in pipeline execution
- Helps explain revenue and cash trends
Clinical trial recruitment outreach
Promotion for Immunocore Holdings plc’s pipeline assets centers on investigator outreach and site activation, which are key to opening Phase I/II and preclinical trials fast. In biopharma, site start-up delays can slow enrollment and push out data readouts, so this outreach is a core go-to-market step, not just admin.
- Targets investigators early.
- Activates trial sites faster.
- Supports patient enrollment.
- De-risks early pipeline timelines.
KIMMTRAK’s OS Win Drives Immunocore’s Evidence-First Growth
Immunocore Holdings plc promotes KIMMTRAK through congress data, peer-reviewed papers, KOLs, and investor updates. The core proof point is the phase 3 OS gain: 21.7 months vs 16.0 months, a 5.7-month lift and a 49% lower death risk. In 2025, this evidence-first mix stayed central for rare oncology adoption and pipeline credibility.
| Channel | Key data |
|---|---|
| Promotion | Phase 3 OS: 21.7 vs 16.0 months |
Price
Premium specialty pricing
KIMMTRAK is a high-value specialty biologic, so Immunocore Holdings plc prices it like rare-disease oncology therapy, not a mass-market drug. In its latest reporting, Immunocore kept KIMMTRAK as the main revenue driver, with 2025 demand still tied to a small metastatic uveal melanoma patient pool and high clinical value. That pricing supports the heavy R&D and manufacturing cost base behind a first-in-class treatment.
Reimbursement-led access
Reimbursement drives access for Immunocore Holdings plc because KIMMTRAK reaches patients only after payer approval. In 2024, Immunocore reported $310.8 million in product revenue, showing that covered oncology use can scale fast.
In oncology, pricing is usually set through health systems and insurers, so reimbursement decisions shape commercial uptake more than list price alone. Strong coverage lowers delays, while weak coverage can block starts even when demand is there.
Hospital buy-and-bill model
Hospital-administered oncology products often use a buy-and-bill model, where the provider buys the drug and bills it under the medical benefit. For Immunocore Holdings plc, this can support tighter control over distribution and more standard claims processing. It also fits hospital buying cycles, where access, reimbursement, and inventory use are tracked closely.
Value-based oncology economics
Immunocore Holdings plc prices KIMMTRAK like a value-based rare-cancer therapy, with payers willing to fund premium immunotherapy when response and survival gains are clear. In the pivotal trial for unresectable or metastatic uveal melanoma, median overall survival was 21.6 months vs 16.9 months with investigator’s choice, supporting strong willingness to pay in an unmet-need setting.
- Rare cancer supports premium pricing
- Survival gain drives payer value
- Unmet need lifts reimbursement
No retail OTC pricing
KIMMTRAK has no retail OTC price because it is prescription-only and is given through specialist care, not sold on a pharmacy shelf. Access is controlled by oncologists and payer authorization, so pricing is negotiated through the medical benefit rather than a consumer checkout model. This fits a high-touch drug with clinic-administered use in metastatic uveal melanoma.
- Prescription-only, not OTC
- No consumer shelf pricing
- Specialist prescribing required
- Payer approval controls access
KIMMTRAK’s survival edge supports premium rare-cancer pricing
Immunocore Holdings plc prices KIMMTRAK as a premium rare-cancer biologic, with payer access tied to survival value, not shelf price. The drug’s pivotal uveal melanoma data showed median overall survival of 21.6 months vs 16.9 months with investigator’s choice, which supports reimbursement at a high medical-benefit price. In 2024, product revenue reached $310.8 million.
| Metric | Value |
|---|---|
| Product revenue | $310.8m |
| Median OS | 21.6 vs 16.9 months |
| Access model | Medical benefit |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.